Nadia Harbeck, MD, PhD, is head of the Breast Center, Oncological Therapy and Clinical Trials Unit, and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) in 1998 and her medical degree from the University of Munich in 1989.
Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based German Working Group for Gynecologic Oncology (AGO) Guidelines for breast cancer therapy (www.ago-online.de). She is the scientific director of the West German Study Group (WSG, www.wsg-online.com). From 2009-2015, she served as an executive board member of the European Organization for Research and Treatment of Cancer (EORTC). Prof Harbeck is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, focusing on trials using novel targeted compounds. She co-chairs the Trans-ALTTO committee. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumors. She also has a special interest in eHealth and is the co-founder of CANKADO (www.cankado.com), a digital patient diary.
Professor Harbeck has authored more than 350 papers in peer-reviewed journals (cumulative impact factor of over 1500) and is coordinating editor-in-chief of Breast Care.
For her clinical translational research, she has received numerous awards.
Professor Harbeck has been an executive or steering committee member for numerous national and international conferences. In 2011, she co-chaired the Third IMPAKT Meeting, and the EORTC-NCI-ASCO Meeting on Molecular Markers. She is a faculty and panel member of the International Consenus Conferences on Breast Cancer in Young Women (BCY), for Advanced Breast Cancer (ABC Lisbon) as well as of the St. Gallen Meeting.
Ваш запрос успешно получен и находится в обработке.
Мы свяжемся с Вами в ближайшее время!